吉西他滨与顺铂二线治疗晚期三阴乳腺癌的效果观察

Efficacy of gemcitabine and cisplatin in the second-line treatment of advanced stage of triple negative breast cancer

目的研究晚期三阴乳腺癌应用吉西他滨与顺铂二线治疗的临床效果。方法选取我院2014年6月至2016年9月收治的晚期三阴乳腺癌患者80例为研究对象,将其按照数字随机化法分为对照组和试验组,各40例。对照组采用常规治疗方式,试验组在对照组的基础上采用吉西他滨联合顺铂进行二线治疗。比较两组患者的临床治疗效果及不良反应发生情况。结果试验组患者的治疗总有效率为82.50%,明显高于对照组的52.50%(P<0.05)。试验组患者的肺部、肝部及胸壁、淋巴结转移部位的治疗总有效率均明显高于对照组(P<0.05)。试验组患者的不良反应总发生率明显低于对照组(P<0.05)。结论晚期三阴乳腺癌应用吉西他滨与顺铂二线治疗的效果显著,并发症发生率低,具有较高临床推广价值。

Objective To study the effect of gemcitabine and cisplatin in the second-line treatment of advanced stage of triple negative breast cancer. Metkods From June 2014 to September 2016, 80 patients with advanced stage of triple nega- tive breast cancer in our hospital were selected as the research objects, and were divided into control group and experi- mental group according to the digital randomization methods, with 40 patients in each group. The control group was treated with conventional treatment, the experimental group was treated with gemcitabine and cisplatin on the basis of the control group. The clinical treatment efficacy and incidence of adverse reactions in the two groups were compared. Results The to- tal effective rate was 82.50% in the experimental group, which was significantly higher than 52.50% in the control group （P〈0.05）. The total effective rates of metastatic sites such as lung, liver and chest wall and lymph node in the experimental group were significantly higher than those of the control group （P〈0.05）. The total incidence of adverse reactions in the ex- perimental group was significantly lower than that of the control group （P〈0.05）. Conclusion Gemcitabine and cisplatin has remarkable effect and lower adverse reactions rate in the second-line treatment of advanced stage of triple negative breast cancer, which has a high clinical promotion value.